Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia

Abstract Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA‐approved agent for management of bleeding in hemophilia patients with inhibitors. Use...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amir M. Ansari, Adam Khorasanchi, Armaghan Faghihimehr, Amir Toor
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	intracranial hemorrhage multiple myeloma platelet transfusion refractoriness recombinant activated FVII thrombocytopenia Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8c32758b797d4d20b4dd364c0121569e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8c32758b797d4d20b4dd364c0121569e
record_format	dspace
spelling	oai:doaj.org-article:8c32758b797d4d20b4dd364c0121569e2021-12-02T07:55:56ZRecombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia2050-090410.1002/ccr3.4788https://doaj.org/article/8c32758b797d4d20b4dd364c0121569e2021-10-01T00:00:00Zhttps://doi.org/10.1002/ccr3.4788https://doaj.org/toc/2050-0904Abstract Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA‐approved agent for management of bleeding in hemophilia patients with inhibitors. Use of recombinant FVIIa has also been used as a last resort in various clinical settings such as trauma, alveolar hemorrhage, gastrointestinal bleeding, and intracranial hemorrhage for control of bleeding with variable outcomes. This paper presents a case of recombinant FVIIa administration in a patient with multiple myeloma and profound transfusion refractory thrombocytopenia suffering from traumatic subdural hematoma.Amir M. AnsariAdam KhorasanchiArmaghan FaghihimehrAmir ToorWileyarticleintracranial hemorrhagemultiple myelomaplatelet transfusion refractorinessrecombinant activated FVIIthrombocytopeniaMedicineRMedicine (General)R5-920ENClinical Case Reports, Vol 9, Iss 10, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	intracranial hemorrhage multiple myeloma platelet transfusion refractoriness recombinant activated FVII thrombocytopenia Medicine R Medicine (General) R5-920
spellingShingle	intracranial hemorrhage multiple myeloma platelet transfusion refractoriness recombinant activated FVII thrombocytopenia Medicine R Medicine (General) R5-920 Amir M. Ansari Adam Khorasanchi Armaghan Faghihimehr Amir Toor Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
description	Abstract Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA‐approved agent for management of bleeding in hemophilia patients with inhibitors. Use of recombinant FVIIa has also been used as a last resort in various clinical settings such as trauma, alveolar hemorrhage, gastrointestinal bleeding, and intracranial hemorrhage for control of bleeding with variable outcomes. This paper presents a case of recombinant FVIIa administration in a patient with multiple myeloma and profound transfusion refractory thrombocytopenia suffering from traumatic subdural hematoma.
format	article
author	Amir M. Ansari Adam Khorasanchi Armaghan Faghihimehr Amir Toor
author_facet	Amir M. Ansari Adam Khorasanchi Armaghan Faghihimehr Amir Toor
author_sort	Amir M. Ansari
title	Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
title_short	Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
title_full	Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
title_fullStr	Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
title_full_unstemmed	Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
title_sort	recombinant activated factor vii in a patient with intracranial hemorrhage and severe thrombocytopenia
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/8c32758b797d4d20b4dd364c0121569e
work_keys_str_mv	AT amirmansari recombinantactivatedfactorviiinapatientwithintracranialhemorrhageandseverethrombocytopenia AT adamkhorasanchi recombinantactivatedfactorviiinapatientwithintracranialhemorrhageandseverethrombocytopenia AT armaghanfaghihimehr recombinantactivatedfactorviiinapatientwithintracranialhemorrhageandseverethrombocytopenia AT amirtoor recombinantactivatedfactorviiinapatientwithintracranialhemorrhageandseverethrombocytopenia
_version_	1718399113382330368

Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia

Ejemplares similares